Evidence map›Paper›PMID 38799251›Full record

ArticleOpen medicine (Warsaw, Poland)2024

Cost-effectiveness of ambroxol in the treatment of Gaucher disease type 2.

Miloš N Milosavljević, Medo Gutić, Vladimir Janjić, Slađana Veselinović, Milan Djordjić, Radenko Ivanović, Jovana Milosavljević, Slobodan M Janković

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open medicine (Warsaw, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Miloš N MilosavljevićDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.
Medo GutićDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.
Vladimir JanjićDepartment of Psychiatry, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.
Slađana VeselinovićDepartment of Communication Skills, Ethics and Psychology, Faculty of Medical Sciences, University of Kragujevac, 3400, Kragujevac, Serbia.
Milan DjordjićDepartment of Communication Skills, Ethics and Psychology, Faculty of Medical Sciences, University of Kragujevac, 3400, Kragujevac, Serbia.
Radenko IvanovićUniversity Hospital Foča, 73300, Foča, Republic of Srpska, Bosnia and Herzegovina.
Jovana MilosavljevićDepartment of Anatomy, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.
Slobodan M JankovićDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Our aim was to compare the costs and efficacy of ambroxol in combination with imiglucerase with the costs and efficacy of imiglucerase only in the treatment of Gaucher disease type 2 (GD2) in the socio-economic settings of the Republic of Serbia, an upper-middle-income European economy. Methods: The perspective of the Serbian Republic Health Insurance Fund was chosen for this study, and the time horizon was 6 years. The main outcomes of the study were quality-adjusted life years gained with ambroxol + imiglucerase and comparator, and direct costs of treatment. The study was conducted through the generation and simulation of the Markov chain model. The model results were obtained after Monte Carlo microsimulation of a sample with 1,000 virtual patients. Results: Treatment with ambroxol in combination with imiglucerase was cost-effective when compared with imiglucerase only and was associated with positive values of net monetary benefit regardless of the onset of the disease. Such beneficial result for ambroxol and imiglucerase combination is primarily driven by the low cost of ambroxol and its considerable clinical effectiveness in slowing the progression of neural complications of GD2. Conclusion: If ambroxol and imiglucerase are used in combination for the treatment of GD2, it is more cost-effective than using imiglucerase alone.

Indexed as

ambroxolcost-effectivenessGaucher diseaseshealthinsurance

Identifiers

PMID38799251
PMCPMC11117451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.